Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$2.35 ▼ -0.25
(-9.61%)
MKT CAP: $19.0M • VOL: 31.2K
52W L $2 52W H $18
ITOC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $523.0K | $448.2K | $628.6K |
| YoY Revenue Growth % | +16.7% | -28.7% | — |
| Gross Profit | $327.4K | $381.2K | — |
| Gross Margin % | 62.6% | 85.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.2M | -$770.3K | -$306.7K |
| Operating Margin % | -80.0% | -80.0% | -48.8% |
| Net Income (GAAP) | -$5.1M | -$660.6K | -$241.2K |
| EBITDA (Normalized) | -$5.2M | -$769.6K | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$3.2M | -$775.0K | -$63.6K |
| Capital Expenditures (CapEx) | $3.8K | $861 | — |
| Free Cash Flow (FCF) | -$3.2M | -$775.9K | -$63.6K |
| FCF Margin % | -80.0% | -80.0% | -10.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.5M | $6.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.1M | $6.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ITOC.